A randomized, non-comparative, multicenter, open-label, phase 2 study of Tarceva (Erlotinib) alone and of Tarceva plus VELCADE (bortezomib) for injection in patients with relapsed or refractory, locally advanced or metastatic non-small cell lung cancer.

Trial Profile

A randomized, non-comparative, multicenter, open-label, phase 2 study of Tarceva (Erlotinib) alone and of Tarceva plus VELCADE (bortezomib) for injection in patients with relapsed or refractory, locally advanced or metastatic non-small cell lung cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2011

At a glance

  • Drugs Bortezomib; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 16 Feb 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
    • 01 Aug 2009 Results have been reported in the Journal of Thoracic Oncology.
    • 05 Jun 2007 Results have been published (1078763).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top